




# Specialised AI screening solutions for the medical industry

## See with certainty

Optain is an international MedTech company, developing advanced AI software solutions.

**Eyetelligence Assure** software analyses full-colour fundus images to screen for referable eye diseases including glaucoma, diabetic retinopathy, and age-related macular degeneration. Additionally, the technology can screen for cardiovascular diseases and provide a risk assessment profile.

Our vision is to harness the power of AI to provide affordable clinical support tools that make **disease screening easy, anytime, anywhere.**



For more information please scan the QR code



optainhealth.com  
info@optainhealth.com

# How Eyetelligence works

## Scanning


Install **Eyetelligence Assure** on a PC or access software online, connect to a fundus camera and take the patient's images.

## Software interface

- Choose the images requiring analysis.
- Receive analysis within seconds for features of common eye diseases.
- Check the results section for a list of the day's patients and results.

## Patient and Clinical Reports

Click to view and download the clinical or patient report, both complete with clinic logo. Reports can be altered to suit conclusions and include notes.



*“AI won't replace clinicians, but clinicians who use AI will replace those who don't.”*

**Dr. Bertalan Meskó**  
The Medical Futurist

# Discover the benefits



**The first line of defence in disease screening**

Quickly alerts patients showing features of glaucoma, neovascular age-related macular degeneration and diabetic retinopathy, with an accuracy of 95%\*.



**Decision support for your existing digital fundus camera**

Seamless integrations provide you with additional decision support to help the development of more informed choices based on the digital fundus images.



**Expert knowledge at your fingertips**

The AI has been trained by a team of sub-specialist ophthalmologists, drawing on more than 200,000 retinal images to help identify signs of serious eye diseases.



**Greater patient certainty, compliance and understanding**

Helps patients better understand clinical assessments through clear and easy-to-understand patient reports and supporting information.

\*AI model has a 95% accuracy rate based on AUC study data, see our website for more details.

### Regulatory Disclaimer

The Eyetelligence software is approved for clinical use in the European Union (CE mark) and Australia and included in the ARTG, the TGA 's register of therapeutic goods, as a Class I medical device. It is intended for the assessment of the retinal vascular system and to screen for microvascular health issues of the body, based on full colour fundus photos that are generated from a fundus camera. The Eyetelligence system outcomes are intended to be subsequently verified and certified by a qualified medical/eye care professional who will make a clinical decision based on a range of inputs not limited to Eyetelligence outcomes.